Identification of the Most Effective Position for Ustekinumab in Treatment Algorithms for Crohn’s Disease
Volume: 19, Issue: 10, Pages: 2082 - 2092.e10
Published: Oct 1, 2021
Abstract
Background & Aims Ustekinumab is a monoclonal antibody against interleukin 12 and interleukin 23 that has been approved by the Food and Drug Administration for treatment of Crohn’s disease (CD). We sought to identify the ideal position for ustekinumab in treatment algorithms for CD. Methods We constructed a Markov model to identify an optimal treatment sequence for CD that included ustekinumab for 1 year or more. The base case was a 35-year old...
Paper Details
Title
Identification of the Most Effective Position for Ustekinumab in Treatment Algorithms for Crohn’s Disease
Published Date
Oct 1, 2021
Volume
19
Issue
10
Pages
2082 - 2092.e10
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History